Clinical Trials
68
Active:4
Completed:6
Trial Phases
5 Phases
Phase 1:33
Phase 2:19
Phase 3:12
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (68 trials with phase data)• Click on a phase to view related trials
Phase 1
33 (48.5%)Phase 2
19 (27.9%)Phase 3
12 (17.6%)Not Applicable
3 (4.4%)Phase 4
1 (1.5%)A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
Not Applicable
Not yet recruiting
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2025-07-17
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT07071714
- Locations
- 🇨🇳
The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
A Clinical Study of SHR-4506 Injection in Patients With Malignant Tumors
Not Applicable
Not yet recruiting
- Conditions
- Malignant Tumors of Adults
- Interventions
- Drug: SHR-4506 Injection
- First Posted Date
- 2025-07-16
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 102
- Registration Number
- NCT07068932
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
🇨🇳Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer
Not Applicable
Recruiting
- Conditions
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2025-07-10
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 96
- Registration Number
- NCT07059221
- Locations
- 🇨🇳
Chongqing University Cancer Hospital, Chongqing, Chongqing, China
🇨🇳West China Hospital of Sichuan University, Chengdu, Sichuan, China
A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors
Phase 2
Recruiting
- Conditions
- For Prevention of Bone Events in Patients With Bone Metastases From Solid Tumors
- Interventions
- Drug: SHR-2017、Denosumab placeboDrug: Denosumab；SHR-2017 placebo
- First Posted Date
- 2025-06-19
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 210
- Registration Number
- NCT07028268
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China
A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors
Phase 2
Not yet recruiting
- Conditions
- Malignant Solid Tumors
- Interventions
- Drug: SHR-4849、SHR-1316、SHR-8068、BP102、carboplatin、cisplatin
- First Posted Date
- 2025-06-19
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT07028281
- Prev
- 1
- 2
- 3
- 4
- 5
- 14
- Next
News
No news found